Treating Depression in the Era of Precision Medicine: Challenges and Perspectives

Michael Musker, Ma-Li Wong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

We are at the dawn of a new era of treatment for major depressive disorder involving precision medicine. Research is using big data, genome-wide association studies, and pharmacogenomics to create a combinatorial biological and environmental model of depression. Biomarkers have already been used to indicate causative pathways and the effectiveness of treatment responses in other areas of medicine. As technology advances, psychiatric practice will be able to use new tools and technology to assist with diagnosis and drug treatment options. The complex interaction of the inherited genome, epigenetic responses, pharmacokinetics, and environmental factors combine to produce endophenotypic outcomes that are predictable. The prevalence and cost burden of depression are so great that improved diagnostic tools are needed. The role of pharmacogenomics and related sciences pharmacokinetics and pharmacodynamics are discussed.
LanguageEnglish
Title of host publicationNeurobiology of Depression
PublisherElsevier
Pages265-275
Number of pages11
DOIs
Publication statusPublished - 2019

Publication series

NameNeurobiology of Depression

Cite this

Musker, M., & Wong, M-L. (2019). Treating Depression in the Era of Precision Medicine: Challenges and Perspectives. In Neurobiology of Depression (pp. 265-275). (Neurobiology of Depression). Elsevier. https://doi.org/10.1016/B978-0-12-813333-0.00023-8
Musker, Michael ; Wong, Ma-Li. / Treating Depression in the Era of Precision Medicine: Challenges and Perspectives. Neurobiology of Depression. Elsevier, 2019. pp. 265-275 (Neurobiology of Depression).
@inbook{8b98261e23a24c2695d8e5e8b9a011b3,
title = "Treating Depression in the Era of Precision Medicine: Challenges and Perspectives",
abstract = "We are at the dawn of a new era of treatment for major depressive disorder involving precision medicine. Research is using big data, genome-wide association studies, and pharmacogenomics to create a combinatorial biological and environmental model of depression. Biomarkers have already been used to indicate causative pathways and the effectiveness of treatment responses in other areas of medicine. As technology advances, psychiatric practice will be able to use new tools and technology to assist with diagnosis and drug treatment options. The complex interaction of the inherited genome, epigenetic responses, pharmacokinetics, and environmental factors combine to produce endophenotypic outcomes that are predictable. The prevalence and cost burden of depression are so great that improved diagnostic tools are needed. The role of pharmacogenomics and related sciences pharmacokinetics and pharmacodynamics are discussed.",
author = "Michael Musker and Ma-Li Wong",
year = "2019",
doi = "10.1016/B978-0-12-813333-0.00023-8",
language = "English",
series = "Neurobiology of Depression",
publisher = "Elsevier",
pages = "265--275",
booktitle = "Neurobiology of Depression",

}

Musker, M & Wong, M-L 2019, Treating Depression in the Era of Precision Medicine: Challenges and Perspectives. in Neurobiology of Depression. Neurobiology of Depression, Elsevier, pp. 265-275. https://doi.org/10.1016/B978-0-12-813333-0.00023-8

Treating Depression in the Era of Precision Medicine: Challenges and Perspectives. / Musker, Michael; Wong, Ma-Li.

Neurobiology of Depression. Elsevier, 2019. p. 265-275 (Neurobiology of Depression).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Treating Depression in the Era of Precision Medicine: Challenges and Perspectives

AU - Musker, Michael

AU - Wong, Ma-Li

PY - 2019

Y1 - 2019

N2 - We are at the dawn of a new era of treatment for major depressive disorder involving precision medicine. Research is using big data, genome-wide association studies, and pharmacogenomics to create a combinatorial biological and environmental model of depression. Biomarkers have already been used to indicate causative pathways and the effectiveness of treatment responses in other areas of medicine. As technology advances, psychiatric practice will be able to use new tools and technology to assist with diagnosis and drug treatment options. The complex interaction of the inherited genome, epigenetic responses, pharmacokinetics, and environmental factors combine to produce endophenotypic outcomes that are predictable. The prevalence and cost burden of depression are so great that improved diagnostic tools are needed. The role of pharmacogenomics and related sciences pharmacokinetics and pharmacodynamics are discussed.

AB - We are at the dawn of a new era of treatment for major depressive disorder involving precision medicine. Research is using big data, genome-wide association studies, and pharmacogenomics to create a combinatorial biological and environmental model of depression. Biomarkers have already been used to indicate causative pathways and the effectiveness of treatment responses in other areas of medicine. As technology advances, psychiatric practice will be able to use new tools and technology to assist with diagnosis and drug treatment options. The complex interaction of the inherited genome, epigenetic responses, pharmacokinetics, and environmental factors combine to produce endophenotypic outcomes that are predictable. The prevalence and cost burden of depression are so great that improved diagnostic tools are needed. The role of pharmacogenomics and related sciences pharmacokinetics and pharmacodynamics are discussed.

UR - https://linkinghub.elsevier.com/retrieve/pii/B9780128133330000238

UR - http://www.mendeley.com/research/treating-depression-era-precision-medicine-challenges-perspectives

U2 - 10.1016/B978-0-12-813333-0.00023-8

DO - 10.1016/B978-0-12-813333-0.00023-8

M3 - Chapter

T3 - Neurobiology of Depression

SP - 265

EP - 275

BT - Neurobiology of Depression

PB - Elsevier

ER -

Musker M, Wong M-L. Treating Depression in the Era of Precision Medicine: Challenges and Perspectives. In Neurobiology of Depression. Elsevier. 2019. p. 265-275. (Neurobiology of Depression). https://doi.org/10.1016/B978-0-12-813333-0.00023-8